Atlanta, GA, United States of America

César Albariño

This inventor holds 1 USPTO granted patent. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2018.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: César Albariño: Innovator in Ebola Detection

Introduction

César Albariño is a notable inventor based in Atlanta, GA (US). He has made significant contributions to the field of infectious disease detection, particularly in relation to the Ebola virus. His work has implications for public health and safety, showcasing the importance of innovation in medical diagnostics.

Latest Patents

César Albariño holds a patent for "Methods and reagents for detecting Ebola virus." This patent includes probes and primers that are essential for detecting EBOV nucleic acid in a sample. The methods disclosed in the patent can be utilized to identify a subject with an EBOV infection, thereby aiding in timely diagnosis and treatment.

Career Highlights

César Albariño is affiliated with the United States of America, as represented by the Secretary, Department of Health and Human Services. His work in this capacity has allowed him to focus on critical health issues, particularly those related to viral infections.

Collaborations

Throughout his career, Albariño has collaborated with esteemed colleagues such as Ute Stroeher and Stuart T Nichol. These partnerships have enhanced the research and development of effective detection methods for infectious diseases.

Conclusion

César Albariño's contributions to the field of Ebola detection exemplify the vital role of inventors in advancing medical science. His innovative approaches are crucial for improving public health responses to viral outbreaks.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…